Abstract
Twelve years ago we reported that lymphocytic alveolitis [or bronchoalveolar lavage (BAL) lymphocytosis] correlates with clinical pulmonary involvement in primary Sjogren’s syndrome (pSS). Our thesis was based οn subtle clinical and functional evidence of interstitial lung disease (ILD) in pSS patients with “high lymphocytic alveolitis” (>15% lymphocytes in BAL). This report is a follow-up study of these patients. Basic clinical and functional re-evaluation of the 22 patients with pSS, studied in 1991, emphasized the differences between those with alveolitis and those without alveolitis. There was no significant functional decline. There were, however, two statistically significant differences between the two groups: (1) only patients with BAL lymphocytosis had to be treated with steroids (5/12 vs. 0/10, P<0.05) and (2) only patients with BAL lymphocytosis had died in the mean time (6/12 vs. 0/10, P<0.01). The causes of death were various. On only two occasions were they related to respiratory infections while there were no deaths from respiratory failure secondary to ILD. BAL lymphocytosis appears to be a surprisingly serious index of dismal prognosis in patients with pSS. We offer no unifying pathophysiologic mechanism for it and, therefore, all we propose is that BAL is performed early, in as many patients with pSS as possible. These patients should then be followed up systematically, in order to evaluate if BAL lymphocytosis has any pathophysiologic importance in the development of clinically serious pSS, which is serious enough to lead to death.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dalavanga YA, Constantopoulos SH, Galanopoulou V, Zerva L, Moutsopoulos HM (1991) Alveolitis correlates with clinical pulmonary involvement in primary Sjogren’s syndrome. Chest 99:1394–1397
Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR (1996) Interstitial lung disease in primary Sjogren’s syndrome Clinical–pathological evaluation and response to treatment. Am J Respir Crit Care Med 154(3 Pt 1):794–799
Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134:136–151
Gross TJ, Hunninghake GW (2001) Idiopathic pulmonary fibrosis. North Engl J Med 345:517–525
Davidson BK, Kelly CA, Griffiths ID (2000) Ten year follow up of pulmonary function in patients with primary Sjognren’s syndrome. Ann Rheum Dis 59:709–712
Manoussakis MN, Tzioufas AG, Pange PJE, Moutsopoulos HM (1986) Serologic profiles in subgroups of patients with Sjogren’s syndrome. Scand J Rheum 61(suppl):89–92
Kelly CA, Foster H, Pal B, Gardiner P, Malcolm AJ, Charles P, Blair GS, Howe J, Dick WC, Griffiths ID (1991) Primary Sjogren’s syndrome in north east England—a longitudinal study. Br J Rheumatol 30:437–442
Wallaert B, Prin L, Hatron PY, Ramon P, Tonnel AB, Voisin C (1987) Lymphocyte subpopulations in bronchoalveolar lavage in Sjogren’s syndrome. Evidence for an expansion of cytotoxic/suppressor subset in patients with alveolar neutrophilia. Chest 92:1025–1031
Hatron PY, Wallaert B, Gosset D, Tonnel AB, Gosselin B, Voisin C, Devulder B (1987) Subclinical lung inflammation in primary Sjogren’s syndrome. Relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease. Arthritis Rheum 30:1226–1231
Constantopoulos SH, Drosos AA, Maddison PJ, Moutsopoulos HM (1984) Xerotrachea and interstitial lung disease in primary Sjogren’s syndrome. Respiration 46:310–314
Shearn MA (1977) Sjogren’s syndrome. Med Clin North Am 61:271–282
Cain HC, Noble PW, Matthay RA (1998) Pulmonary manifestations of Sjogren’s syndrome. Clin Chest Med 19:687–699
Mialon P, Barthelemy L, Sebert P, Le Henaff C, Sarni D, Pennec YL, Le Goff P, Youinou P (1997) A longitudinal study of lung impairment in patients with primary Sjogren’s syndrome. Clin Exp Rheumatol 15:349–354
Papiris SA, Saetta M, Turato G, La Corte R, Trevisani L, Mapp CE, Maestrelli P, Fabbri LM, Potena A (1997) CD4-positive T-lymphocytes infiltrate the bronchial mucosa of patients with Sjogren’s syndrome. Am J Respir Crit Care Med 156(2 Pt 1):637–641
Papiris SA, Maniati M, Constantopoulos SH, Roussos C, Moutsopoulos HM, Skopouli FN (1999) Lung involvement in primary Sjogren’s syndrome is mainly related to the small airway disease. Ann Rheum Dis 58:61–64
Moutsopoulos HM (1994) Sjogren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 72:162–165
Skopouli FN, Moutsopoulos HM (1994) Autoimmune epithelitis: Sjogren’s syndrome. Clin Exp Rheumatol 12(Suppl 11):S9–S11
Theander E, Manthorpe R, Jacobsson LT (2004) Mortality and causes of death in primary Sjogren’s syndrome. Arthritis Rheum 50:1262–1269
Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum 46:741–747
Dalavanga YA, Constantopoulos SH, Zerva LB, Trekli M, Kotoulas OO, Moutsopoulos HM (1992) Liquid phase characteristics of bronchoalveolar lavage in primary Sjogren’s syndrome. Chest 102:1085–1807
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dalavanga, Y., Voulgari, P., Georgiadis, A. et al. Lymphocytic alveolitis: a surprising index of poor prognosis in patients with primary Sjogren’s syndrome. Rheumatol Int 26, 799–804 (2006). https://doi.org/10.1007/s00296-005-0092-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-005-0092-1